- Home
- AMPX vs PROK Comparison
AMPX vs PROK Comparison
Compare AMPX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPX
- PROK
- Stock Information
- Founded
- AMPX 2008
- PROK 2015
- Country
- AMPX United States
- PROK United States
- Employees
- AMPX N/A
- PROK 163
- Industry
- AMPX Industrial Machinery/Components
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMPX Miscellaneous
- PROK Health Care
- Exchange
- AMPX Nasdaq
- PROK Nasdaq
- Market Cap
- AMPX 261.0M
- PROK 212.4M
- IPO Year
- AMPX N/A
- PROK N/A
- Fundamental
- Price
- AMPX $3.35
- PROK $1.66
- Analyst Decision
- AMPX Strong Buy
- PROK Buy
- Analyst Count
- AMPX 7
- PROK 5
- Target Price
- AMPX $8.43
- PROK $4.50
- AVG Volume (30 Days)
- AMPX 5.2M
- PROK 566.3K
- Earning Date
- AMPX 11-07-2024
- PROK 11-12-2024
- Dividend Yield
- AMPX N/A
- PROK N/A
- EPS Growth
- AMPX N/A
- PROK N/A
- EPS
- AMPX N/A
- PROK N/A
- Revenue
- AMPX $17,480,000.00
- PROK N/A
- Revenue This Year
- AMPX $132.87
- PROK N/A
- Revenue Next Year
- AMPX $234.98
- PROK N/A
- P/E Ratio
- AMPX N/A
- PROK N/A
- Revenue Growth
- AMPX 196.22
- PROK N/A
- 52 Week Low
- AMPX $0.61
- PROK $1.18
- 52 Week High
- AMPX $4.70
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- AMPX 59.22
- PROK 46.29
- Support Level
- AMPX $3.17
- PROK $1.50
- Resistance Level
- AMPX $3.90
- PROK $1.90
- Average True Range (ATR)
- AMPX 0.64
- PROK 0.15
- MACD
- AMPX 0.02
- PROK -0.01
- Stochastic Oscillator
- AMPX 57.46
- PROK 45.45
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high energy density lithium-ion batteries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. All of its revenues is geographically earned in the United States.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.